Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients
Crossref DOI link: https://doi.org/10.1007/s13365-016-0445-4
Published Online: 2016-05-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Achiron, Anat
Miron, Gadi
Zilkha-Falb, Rina
Magalashvili, David
Dolev, Mark
Stern, Yael
Gurevich, Michael
Funding for this research was provided by:
Medison Pharma SRL, Israel (8343-10-SNC)
Text and Data Mining valid from 2016-05-11